Publication:
Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1

1
0

Issued Date

2019

Resource Type

Article

File Type

application/pdf

ISSN

16643828

DOI

10.1159/000496472

Other identifier(s)

2-s2.0-85064930982

Rights Holder(s)

Scopus

Bibliographic Citation

CardioRenal Medicine. Vol 9, No.4 (2019), p.212-221

Suggested Citation

Lertdumrongluk P., Streja E., Rhee C.M., Moradi H., Chang Y., Reddy U., Tantisattamo E., Kalantar-Zadeh K., Kopp J.B. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1. CardioRenal Medicine. Vol 9, No.4 (2019), p.212-221. doi:10.1159/000496472 Retrieved from: https://hdl.handle.net/20.500.14740/5299

Title

Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1

Author(s)

Lertdumrongluk P.
 Streja E.
 Rhee C.M.
 Moradi H.
 Chang Y.
 Reddy U.
 Tantisattamo E.
 Kalantar-Zadeh K.
 Kopp J.B.

Abstract

Background: Observational studies show that African American (AA) dialysis patients have longer survival than European Americans. We hypothesized that apolipoprotein L1 (APOL1) genetic variation, associated with nephropathy in AAs, contributes to the survival advantage in AA dialysis patients. Methods: We examined the association between race and mortality among 37,097 adult dialysis patients, including 54% AAs and 46% European Americans from a large dialysis organization (entry period from July 2001 to June 2006, follow-up through June 2007), within each cause of end-stage renal disease (ESRD) category associated with APOL1 renal risk variants using Cox proportional hazard models. Results: AA dialysis patients had numerically lower mortality than their European American counterparts for all causes of ESRD. The mortality reduction among AAs compared to European Americans was statistically significant in patients with ESRD attributed to diabetes mellitus, hypertension, and APOL1-enriched glomerulonephritis (GN) (HR [95% CI]: 0.69 [0.66-0.72], 0.73 [0.68-0.79], and 0.89 [0.79-0.99], respectively); these are conditions in which APOL1 variants promote kidney disease. By contrast, the significant survival advantage of AA dialysis patients was not observed in patients with ESRD attributed to other kidney disease (including polycystic kidney disease, interstitial nephritis, and pyelonephritis) and other GN, which are not associated with APOL1 variants. Conclusions: These data suggest the hypothesis that the relative survival advantage of AA dialysis patients may be related to APOL1 variation. Further large population-based genetic studies are required to test this hypothesis. © 2019 Published by S. Karger AG, Basel.

Subject(s)

Apolipoprotein L1
 APOL1 protein, human
 Apolipoprotein L1
 Adult
 African American
 All cause mortality
 Antiretroviral therapy
 Article
 Cancer staging
 Cardiovascular mortality
 Cohort analysis
 Diabetes mellitus
 Dialysis
 End stage renal disease
 Female
 Genetic variation
 Glomerulonephritis
 Glomerulosclerosis
 Heart arrest
 Heart failure
 Hemodialysis
 Hospitalization
 Human
 Hypertension
 Kidney transplantation
 Major clinical study
 Male
 Middle aged
 Mortality rate
 Observational study
 Peritoneal dialysis
 Prevalence
 Priority journal
 Race
 Renal replacement therapy
 Survival rate
 Adolescent
 African American
 Caucasian
 Cause of death
 Chronic kidney failure
 Epidemiology
 Genetic predisposition
 Genetics
 Hemodialysis
 Mortality
 Proportional hazards model
 United States
 Young adult
 Adolescent
 Adult
 African Americans
 Apolipoprotein L1
 Cause of Death
 European Continental Ancestry Group
 Female
 Genetic Predisposition to Disease
 Genetic Variation
 Humans
 Kidney Failure, Chronic
 Male
 Middle Aged
 Proportional Hazards Models
 Renal Dialysis
 United States
 Young Adult

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/5299

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By